Ignite Creation Date:
2025-12-24 @ 4:50 PM
Ignite Modification Date:
2026-02-08 @ 6:37 AM
Study NCT ID:
NCT02481050
Status:
COMPLETED
Last Update Posted:
2018-11-15
First Post:
2015-06-17
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
Sponsor:
Eisai Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-06-16
Start Date Type:
ACTUAL
Primary Completion Date:
2016-12-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-09-05
Completion Date Type:
ACTUAL
First Submit Date:
2015-06-17
First Submit QC Date:
None
Study First Post Date:
2015-06-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-10-18
Results First Submit QC Date:
None
Results First Post Date:
2018-11-15
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-10-18
Last Update Post Date:
2018-11-15
Last Update Post Date Type:
ACTUAL